The Indonesian experience in HPV vaccine procurement highlights the transition from Gavi support to full self-financing within the national immunization program. Facing high cervical cancer incidence, the country initiated phased rollouts since 2016, progressing to nationwide coverage in 2022. Post-Gavi strategies include technology transfer to Biofarma for local vaccine production and cost reduction. Key challenges involve ensuring consistent supply, maintaining quality, and managing budget constraints amid policy shifts. Strong political commitment and recommendations for single-dose regimens are central to sustaining program scale-up and financial viability.